AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02496403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Medical Management (SMM)
Description: SMM is designed to provide basic advice about opioid dependence and encouragement to adhere to treatment recommendations. Sessions provide support and monitoring of medication compliance, dose, withdrawal, adverse effects, and discussion of medical complications of opioid and other drug use. Early in treatment, the focus will be on helping patients adjust to the medications (e.g., monitoring withdrawal or other adverse symptoms, tolerating discomfort, curtailing illicit drug use, and referral to self-help). As treatment progresses, the practitioner may focus more on educating the patient about the social and behavioral factors perpetuating addiction and encourage behavioral and lifestyle change to support recovery.
Study NCT04440644 — intervention group
Intervention type: BEHAVIORAL
Intervention: BBI
Description: administration of psychometric test
Study NCT03333174 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cardiorespiratory monitoring
Description: The investigators will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations)
Study NCT03333174 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory monitoring
Description: The investigators will use high resolution physiologic monitoring of Heart Rate, Respiratory Rate, Pulse oximetry, (and near-infrared monitoring as well as microcapnography in selected infants) to evaluate control of breathing (apnea, bradycardia, desaturations)
Study NCT04412252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: 10 mg tofacitinib administered as two 5 mg tablets or solution taken orally twice daily for 14 days
Study NCT04412252 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tofacitinib-matching placebo administered as tablets or solution taken orally twice daily for 14 days
Study NCT03263182 — intervention group
Intervention type: BEHAVIORAL
Intervention: Introduction of the Safe Childbirth Checklist
Description: 1. Adaptation of the SCC tool to Zambia: In order to produce a tool that is fully relevant to the Zambian context, a team of clinical experts from the MOH adapted the language of the SCC.~2. Training of trainers on the SCC by international experts: Ariadne Labs has designed a training-of-trainers (TOT) for coach training to support quality improvement initiatives, including the implementation of the WHO SCC. Members of the district mentorship team for Nchelenge District will receive this type of TOT training.~3. Following the TOT session, the district mentorship team will conduct facility-level training for health workers on using the SCC. Within target facilities, all public sector health workers will be invited to participate in the training.~4. Mentorship and support to facility-level health workers on using the SCC: The district mentorship team will carry out coaching and support visits to health facilities following the initial SCC training.
Study NCT00672386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily for 12 weeks
Study NCT03875079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6874281
Description: Part I Safety Run in:~Cohort 1.1: RO6874281 will be administered by intravenous (IV) infusion; 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (i.e. 6 weeks) in order to confirm the safety of the proposed dose and schedule that will be used in Part II of this study.~Cohort 1.2: RO6874281 will be administered by IV infusion via an induction and maintenance phase; 10 mg (QW) every week for 3 weeks followed by 10 mg (Q3W) every 3 weeks and will be observed over 2 administration cycles (6 weeks) to confirm safety of the proposed dose and schedule to be used in Part III of this study.~Part II Expansion: RO6874281 will be administered by IV infusion; 10 mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohort 1.1 outcome).~Part III Expansion: RO6874281 will be administered by IV infusion; 10 mg (QW) every week or 10mg (Q3W) every 3 weeks (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes) in either a Q3W or QW/Q3W schedule.
Study NCT03875079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Part I Safety Run in (Cohorts 1.1 and 1.2): Pembrolizumab will be administered by IV; 200 mg Q3W and will be observed over 2 administration cycles (i.e. 6 weeks).~Part II Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohort 1.1 outcome)~Part III Expansion: Pembrolizumab will be administered by IV; 200 mg Q3W (or lower dose level depending on Part I Cohorts 1.1 and 1.2 outcomes)
Study NCT02888067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium bromide 0.5 mg/kg
Description: Moderate neuromuscular blockade with rocuronium bromide
Study NCT02888067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium bromide 1.0 mg/kg
Description: Deep neuromuscular blockade with rocuronium bromide
Study NCT02888067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex sodium 2 mg/kg
Description: Reversal with sugammadex sodium
Study NCT02888067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex sodium 4 mg/kg
Description: Reversal with sugammadex sodium
Study NCT03267290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sonazoid- CEUS, CEMRI, CECT
Description: Sonazoid- CEUS+CEMRI in a characterization of HCC, in comparison with CECT+CEMRI.
Study NCT02222519 — intervention group
Intervention type: DRUG
Intervention: Rocuronium
Description: Rocuronium 0.6mg/kg iv single dose
Study NCT04882761 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant
Description: Comparative
Study NCT00672386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study.
Study NCT00672386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study.
Study NCT00672386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: Participants will receive dietary counseling at Screening, Week 4, 8, 12, and will be instructed to remain on a calorically appropriate diet with a maximum of 30% of calories derived from fat (in accordance with local practice guidelines for the treatment of type 2 diabetes mellitus) during the entire study.
Study NCT00672386 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary Counseling
Description: Participants will receive dietary counseling at Screening, Week 4, 8, 12, and will be instructed to remain on a calorically appropriate diet with a maximum of 30% of calories derived from fat (in accordance with local practice guidelines for the treatment of type 2 diabetes mellitus) during the entire study.
Study NCT03961386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FallsTalk-C
Description: The FT-C experimental intervention involves two face-to-face visits including Initial and Follow-up Interviews, CG training, daily interaction with the PwD using a computer with FT-C software, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
Study NCT03961386 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FallsTalk
Description: The FallsTalk intervention involves two face-to-face visits including Initial and Follow-up Interviews,CG training, daily interaction with the PwD, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
Study NCT03961386 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FallsTalk
Description: The FallsTalk intervention involves two face-to-face visits including Initial and Follow-up Interviews,CG training, daily interaction with the PwD, weekly check-in calls, weekly postcard completion and monthly check-in calls for at least six months and up to one year.
Study NCT03026140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3mg/kg (day 1 and day 15), administered neoadjuvant before surgery
Study NCT03026140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg (day 1) ,administered neoadjuvant before surgery
Study NCT03026140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg
Description: celecoxib will be administered starting day 1 until 1 day before surgery daily (if patient is randomized to group 2 (only applicable for patients with a MSS tumor)
Study NCT03026140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: BMS-986253 2400mg IV will be administered on day 1 and 15 (only applicable for patients with MSS tumors)
Study NCT03026140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986016
Description: Relatlimab will be administered IV, in cohort 5 240mg on day 1 and day 15, in cohort 6 480mg on day 1 and day 29
Study NCT02958280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit&Sober App
Description: Fit\&Sober is a smartphone-based physical activity app that includes multilevel strategies for increasing physical activity for patients with AUDs in early recovery.
Study NCT02958280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Advice
Description: Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
Study NCT02958280 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice
Description: Participants randomized to the BA only condition will meet for a 30-minute discussion with a research staff member. In this session, participants will receive information about the public health guidelines for physical activity, the benefits of physical activity for physical and mental health, as well as sobriety, strategies for getting started as well as instruction on gradually increasing physical activity
Study NCT03118141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blastocyst morphologic score
Description: Blastocysts will be scored by Gardner morphologic criteria.
Study NCT03118141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blastocyst biopsy and sequencing
Description: Three blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
Study NCT03118141 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: freeze-all and single thawed blastocyst transfer
Description: All blastocysts will be vitrified in fresh cycle. Single blastocyst will be thawed and transferred.
Study NCT01612637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training and lifestyle advice
Description: Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship and information that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
Study NCT01612637 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle advice
Description: Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
Study NCT04446845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double Stimulation (Elonva+rFSH) in luteal /follicular phase
Description: Following the 2nd oocyte retrieval, the patient will start luteal phase support (LPS) with vaginal micronized progesterone 200mg x 3 times a day until the day of the pregnancy test. All embryos will be cultured until day 5 in time-lapse incubators. In case of no blastocyst in the second cycle, or in case of poor embryo quality and in case of availability of frozen embryos from the first stimulation cycle, 1 frozen blastocyst from the first cycle will be thawed and will be transferred 5 days following the 2nd oocyte retrieval. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of ovarian hyperstimulation syndrome (OHSS) or progesterone elevation which is considered clinically relevant on the day of human chorionic gonadotropin (hCG) trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
Study NCT00596024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lutein/zeaxanthin
Description: daily supplementation of lutein and zeaxanthin at dose of 12 mg/day
Study NCT00596024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules with the same size and coating as those of lutein/zeaxanthin supplements without active ingredients
Study NCT03646903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification
Description: Cognitive bias modification (CBM) interventions typically involve the completion of brief, web-based tasks in which individuals are presented with a series of stimuli (e.g., words, sentences) and trained to respond in a manner that is positive or neutral, rather than negative and unhelpful. CBM interventions rely on the premise that repeated reinforcement of adaptive cognitions and a reshaping of negative cognitions enhance functioning and reduce distress.
Study NCT03646903 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Bias Modification
Description: Cognitive bias modification (CBM) interventions typically involve the completion of brief, web-based tasks in which individuals are presented with a series of stimuli (e.g., words, sentences) and trained to respond in a manner that is positive or neutral, rather than negative and unhelpful. CBM interventions rely on the premise that repeated reinforcement of adaptive cognitions and a reshaping of negative cognitions enhance functioning and reduce distress.
Study NCT03646903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Psychoeducation-based interventions rely on the premise that enhancing knowledge about psychiatric symptoms and treatment will facilitate treatment engagement.
Study NCT04446845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Stimulation (Elonva+rFSH) in follicular phase
Description: From the day of oocyte retrieval, the patients will be asked to start the LPS with vaginal micronized progesterone 3 times a day until the day of the pregnancy test. Embryo transfer will be performed in all patients with available blastocysts, except in cases of high risk of OHSS or progesterone elevation which is considered clinically relevant on the day of hCG trigger, in which freeze-all strategy and deferred frozen embryo transferred will be considered.
Study NCT03061201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-525 (PF-07055480)
Description: Single dose of investigational product SB-525 (PF-07055480)
Study NCT01191775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNT2258
Description: Patients will receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks). The treatment cycle repeats every 3 weeks for up to 6 cycles in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the study.
Study NCT02027662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osvaren Granules
Study NCT02027662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osvaren film-coated tablets
Study NCT03156179 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: calcium isotope analysis
Description: A dual stable calcium isotope method will be used to determine fractional calcium absorption. Two stable calcium isotopes will be administered to participants in order to determine fractional calcium absorption. 7 mg of 44Ca will be administered orally in 60 mL of liquid at the start of the study. 2 mg of 42Ca will then be administered intravenously. 24 hour urine collection will begin immediately following oral tracer administration for the assessment of urinary calcium excretion. The enrichment of 44Ca and 42Ca in urine will be determined by magnetic sector thermal ionization mass spectrometry. The isotopic ratios of 44Ca and 42Ca to 48Ca (another naturally occurring calcium isotope present in the human body) will be calculated (42Ca/48Ca and 44Ca/48Ca). The relative fraction of the oral to intravenously administered isotope in the 24 hour urine sample \[(42Ca/48Ca) / (44Ca/48Ca)\] is the fractional calcium absorption.
Study NCT00536224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full counseling
Description: The health educator generated a computerized report for the patient that outlined his/her Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal. Based on the Ask-Advise-Assess-Assist-Arrange follow-up (5A's) framework for behavior change, counseling for specific risk-related behaviors (diet, physical activity, and smoking) was provided by a cardiovascular rehabilitation health educator in the emergency department and during telephone follow-up (2 sessions over 6 weeks). Patients also received a general informational handout on self-management of cardiovascular risk factors (AHA Brochure Controlling your risk factors). A full report was also be sent to the patient's primary care physician (if any) at the conclusion of counseling.
Study NCT00536224 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal counseling
Description: Patients assigned to the minimal counseling intervention received brief counseling (\<5 minutes) on the benefits of changing lifestyle and a handout with general information on self-management of cardiovascular risk factors.~Patients assigned to minimal intervention also received an AHA brochure (Controlling your risk factors) with general information on management of cardiovascular risk factors. At the end of 6-month follow-up, patients received a computerized report that outlined their Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal.
Study NCT00347919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib (GW786034) 400 mg
Description: 400 mg administered orally once daily
Study NCT00347919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib (GW572016) 1500 mg
Description: 1500 mg administered orally once daily.
Study NCT00347919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib (GW572016) 1000 mg
Description: 1000 mg administered orally once daily
Study NCT00347919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib (GW786034) 800 mg
Description: 800 mg administered orally once daily
Study NCT01968707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ChloraPrep Hi-Lite Orange
Description: Apply topically.
Study NCT01968707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Apply topically.
Study NCT01968707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Prep Tint 10.5-mL
Description: Apply topically.
Study NCT01968707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3M CHG/IPA Prep Tint 26-mL
Description: Apply topically
Study NCT04424212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group CoronaCope
Description: Intervention based on cognitive behavioural therapy principles and adapted to the coronavirus pandemic situation. Intervention's main purpose is to mental health issues such as depressive symtoms, stress, worry and anxiety related to the coronavirus pandemic and increase quality of life in the current situation. Intervention contains psycho-educational elements as well as examples and exercises.
Study NCT00765895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nortriptyline Hydrochloride
Description: Nortriptyline; 10 mg, one capsule, po qhs (by mouth at bedtime each night) x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks, f06 visit, 50 mg, two capsules, po qhs x 3 weeks, f09 visit, 75 mg, three capsules, po qhs x 6 weeks, f15 visit: taper study drug by one capsule a week, off study drug for the last week
Study NCT00765895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for nortriptyline)
Description: Placebo (for nortriptyline), 10 mg, one capsule, po qhs x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks;
Study NCT04842188 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: L-PRF with aPDT
Description: surgical open flap debridement followed by L-PRF with aPDT